奥泰生物
(688606)
| 流通市值：53.19亿 | | | 总市值：53.19亿 |
| 流通股本：7928.09万 | | | 总股本：7928.09万 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 429,850,024.75 | 208,475,751.58 | 866,582,952.58 | 618,025,472.14 |
| 营业收入 | 429,850,024.75 | 208,475,751.58 | 866,582,952.58 | 618,025,472.14 |
| 二、营业总成本 | 299,110,577.78 | 143,277,319.88 | 571,937,182.55 | 425,103,891.99 |
| 营业成本 | 186,926,166.19 | 92,500,751.86 | 383,743,801.78 | 273,429,699.73 |
| 税金及附加 | 4,039,473.17 | 2,933,860.99 | 9,565,171.69 | 4,774,025.45 |
| 销售费用 | 38,436,383.21 | 14,008,023.23 | 55,388,921.47 | 41,885,987.45 |
| 管理费用 | 34,605,227.94 | 15,047,510.18 | 64,841,632.7 | 45,636,701.66 |
| 研发费用 | 48,195,711.85 | 21,152,185.22 | 95,824,901.05 | 71,504,941.41 |
| 财务费用 | -13,092,384.58 | -2,365,011.6 | -37,427,246.14 | -12,127,463.71 |
| 其中:利息费用 | 100,232.85 | 55,903.58 | 415,350.86 | 366,181.49 |
| 其中:利息收入 | 13,241,292.78 | 2,271,240.09 | 33,468,165.72 | 17,858,437.69 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 15,823,882.7 | 2,101,122.21 | 35,548,454.9 | 22,550,628.77 |
| 加:投资收益 | 6,084,326.45 | 517,478.78 | 12,194,620.55 | 11,590,830.28 |
| 资产处置收益 | - | - | 1,224,694.32 | 3,480,365.44 |
| 资产减值损失(新) | -608,005.17 | -100,097.18 | -9,071,584.44 | -7,314,634.97 |
| 信用减值损失(新) | -4,996,527.44 | -4,499,759.64 | -7,790,927.99 | -13,940,234.76 |
| 其他收益 | 5,537,749.4 | 1,357,605.08 | 18,766,875.51 | 17,493,941.76 |
| 四、营业利润 | 152,580,872.91 | 64,574,780.95 | 345,517,902.88 | 226,782,476.67 |
| 加:营业外收入 | 0.3 | - | 3,186,384.61 | 179,812.1 |
| 减:营业外支出 | 473,485.47 | 54,959.48 | 990,907.36 | 3,644,577.57 |
| 五、利润总额 | 152,107,387.74 | 64,519,821.47 | 347,713,380.13 | 223,317,711.2 |
| 减:所得税费用 | 20,005,582.88 | 3,340,800.48 | 44,803,527.41 | 25,772,550.07 |
| 六、净利润 | 132,101,804.86 | 61,179,020.99 | 302,909,852.72 | 197,545,161.13 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 132,101,804.86 | 61,179,020.99 | 302,909,852.72 | 197,545,161.13 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 132,012,694.61 | 61,216,292.5 | 302,471,981.38 | 197,526,404.8 |
| 少数股东损益 | 89,110.25 | -37,271.51 | 437,871.34 | 18,756.33 |
| 扣除非经常损益后的净利润 | 109,435,369.36 | 58,348,017.52 | 237,533,231.26 | 154,329,626.6 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 1.67 | 0.77 | 3.82 | 2.49 |
| (二)稀释每股收益 | 1.67 | 0.77 | 3.82 | 2.49 |
| 八、其他综合收益 | -647,348.27 | -276,672.56 | 1,762,140.42 | -1,478,128.56 |
| 归属于母公司股东的其他综合收益 | -644,840.25 | -274,164.54 | 1,745,866.01 | -1,478,414.22 |
| 九、综合收益总额 | 131,454,456.59 | 60,902,348.43 | 304,671,993.14 | 196,067,032.57 |
| 归属于母公司股东的综合收益总额 | 131,367,854.36 | 60,942,127.96 | 304,217,847.39 | 196,047,990.58 |
| 归属于少数股东的综合收益总额 | 86,602.23 | -39,779.53 | 454,145.75 | 19,041.99 |
| 公告日期 | 2025-08-30 | 2025-04-29 | 2025-04-29 | 2024-10-31 |
| 审计意见(境内) | | | 标准无保留意见 | |